IMCR - Immunocore Holdings

-

$undefined

N/A

(N/A)

Immunocore Holdings NasdaqGS:IMCR Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Location: 92 Park Drive, Abingdon, OX14 4RY, United Kingdom | Website: https://www.immunocore.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.357B

Cash

837M

Avg Qtr Burn

N/A

Short % of Float

21.25%

Insider Ownership

5.18%

Institutional Own.

97.43%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KIMMTRAK (Tebentafusp) (gp100) Details
Metastatic uveal melanoma, Melanoma, Cancer

Approved

Quarterly sales

KIMMTRAK (Tebentafusp) (gp100) Details
Metastatic uveal melanoma, Cancer, Melanoma

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Update

IMC-R117C [PIWIL1-A02 targeted] Details
Cancer, Colorectal cancer , Gastrointestinal stromal tumors

Phase 1/2

Data readout

IMC-F106C (Brenetafusp) Details
Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer

Phase 1/2

Data readout

IMC-M113V (Gag-A02) Details
Viral infection, Human immunodeficiency virus

Phase 1/2

Update

Phase 1/2

Update

Phase 1

Data readout

IMC-I109V Details
Viral infection, Hepatocellular carcinoma, Hepatitis B

Phase 1

Data readout

IMC-C103C Details
Ovarian cancer, Head and neck cancer, Cancer, Non-small cell lung carcinoma, Gastric cancer, Solid tumor/s

Phase 1

Update

IMC-U120AI Details
Atopic dermatitis

IND

Submission

IMC-S118AI Details
Type 1 Diabetes

IND

Submission